Aleksey Gerasyuto

Aleksey Gerasyuto is an accomplished chemist with extensive experience in drug discovery and medicinal chemistry. As Senior Vice President at Schrödinger from January 2020 to January 2025, Aleksey led the Medicinal Chemistry Team and co-led the strategic oversight of the Therapeutic Group Discovery Portfolio. Previous roles include Vice President at Schrödinger, where Aleksey was instrumental in establishing a collaboration with Novartis, and Executive Director, overseeing the successful Wee1/Myt1 program, which led to the first-in-class drug SGR-3515. Prior to Schrödinger, Aleksey held positions at PTC Therapeutics, contributing to programs targeting Huntington disease and antibacterial agents. Aleksey began a career in research at the N. D. Zelinsky Institute of Organic Chemistry and holds a Ph.D. in Chemistry from the University of Wisconsin-Madison.